Sudarshan Pharma Industries Ltd submitted an updated investor presentation to the BSE on August 14, 2026, detailing its proposed acquisition of a USFDA-approved manufacturing facility. The disclosure, made pursuant to Regulation 30 of SEBI’s Listing Obligations and Disclosure Requirements Regulations, 2015, outlines the operational and regulatory profile of the target plant located in Visakhapatnam.

The facility, spread across 14 acres and situated 40 km from Visakhapatnam Airport, specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs) and API intermediates. It does not produce steroids, penicillin, beta-lactam antibiotics, hormones, or cytotoxic products. The site benefits from infrastructural support provided by the Andhra Pradesh Industrial Infrastructure Corporation (APIIC), including water supply, a common effluent treatment plant, hazardous waste management, and a marine outfall for treated effluents.

Regulatory Approvals and Certifications

The target facility holds critical regulatory approvals that validate its compliance with international quality standards. Key certifications include:

• USFDA: Approved in 2024 (ANDA-217608)
• WHO Geneva: Audited and accepted in 2024
• ANVISA: Approved in 2025
• ISO Standards: Certified for ISO 9001:2015 (QMS), ISO 14001:2015 (OH & SMS), and ISO 45001:2018 (EMS)
• State Approval: Accredited manufacturing license and GMP certificate from the Drug Control Authority, Government of Andhra Pradesh

Manufacturing Capacity and Infrastructure

The plant operates four manufacturing blocks and a solvent recovery system, functioning on a 24/7 basis to meet customer timelines. The total installed capacity stands at 584 KL, distributed across multi-product facilities.

The facility is equipped with stainless steel (SS 316) equipment, including stirred stainless steel reactors (SSR), glass-lined reactors (GLR), tray dryers, vacuum tray dryers (VTD), and fluid bed dryers. Utilities include a 1010 KV generator and a 500 KV generator for power backup, along with dedicated steam, cooling, and purified water systems.

Workforce and Leadership

The site employs approximately 200 personnel, with the majority allocated to production (90 employees) and engineering & projects (42 employees). Quality control and assurance are managed by 24 and 15 staff members, respectively.

Key leadership includes Mr. CH.V. Ram Prasad (DGM-Production) with 35 years of experience, Mr. Dr. S. Rama Rao (DGM-QA) with 19 years, and Mr. CH.V. Suryanarayana (GM-R&D) with 20 years. The team has extensive audit exposure to regulators including USFDA, EDQM, WHO, and ANVISA, having previously worked with companies such as Laurus Labs, Granules, and Hetero Labs.

Product Portfolio and Customer Base

The facility manufactures intermediates for therapeutic categories including antiretrovirals (e.g., Lamivudine, Emtricitabine, Dolutegravir), antihistamines (Levocetirizine), antifungals (Fluconazole), and respiratory drugs (Ambroxol). The only finished API listed is Lamivudine (USP/IP grade).

Major Customers

The plant serves a diverse clientele across domestic and export markets:

• Export Customers: Bayer Limited, Shanghai Desano Pharmaceutical Co., Ltd, Blanver, Interquim, Ercros, Nanjing, Tabuk, Alliance, Zach, Jaingsu Coben, and Fabric Italiana.
• Domestic Customers: Laurus Labs Limited, Mylan Laboratories Limited, Cipla Limited, Emcure Pharma, Atul Bioscience Limited, Glenmark Life Sciences Pvt Ltd, Macleods, Hetero, Dr. Reddy’s, MSN Laboratories, Granules Limited, Aditri Pharma, Micro Labs, Delta Bio Pharma, 4 Care Life Sciences, Unicure, Solara, Diavat, and Syngene.

What the Numbers Show

The facility’s regulatory footprint demonstrates significant compliance maturity, having secured USFDA and WHO approvals in 2024 followed by ANVISA approval in 2025. This sequential validation suggests a robust quality management system capable of meeting stringent global standards. Furthermore, the customer list includes major pharmaceutical players like Bayer, Cipla, and Laurus Labs, indicating that the acquired unit likely contributes to established supply chains rather than requiring extensive new business development post-acquisition.

Promoter Hemal Mehta of Sudarshan Pharma Industries has released the pledge on 20,00,000 equity shares, reducing his encumbered holding to zero. The un-pledge, which represents 0.83% of the company’s total share capital, was executed on August 6, 2026, and disclosed to the stock exchanges on August 8, 2026, under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This move removes all outstanding encumbrances from Mehta’s stake, potentially easing concerns regarding promoter liquidity and collateral risk for lenders and investors.

The disclosure, filed with BSE Limited, confirms that the shares were previously pledged in favor of Mr. Kirit Ratilal Shah. The original encumbrance was created due to a loan taken by the promoter for personal reasons. With the release of these shares, the number of encumbered shares held by Mehta has dropped from 20,00,000 to nil. There were no new pledges or liens created during this period.

Pledge Status Details

Mehta continues to hold a substantial stake of 6,40,21,020 shares, accounting for 26.60% of the total share capital. The release of the pledge indicates that the underlying loan obligation has been settled or restructured without requiring continued collateral against these specific shares.

What This Means

The complete removal of encumbrances from the promoter’s holding is a positive signal for corporate governance and financial stability. Promoter pledging is often viewed as a proxy for personal liquidity stress; when promoters pledge significant portions of their holdings, it raises the risk of forced sell-offs if the stock price declines or if margin calls are triggered by lenders. By clearing the pledge entirely, Mehta demonstrates improved financial flexibility. For investors, this reduces the overhang of potential dilution or distress sales associated with pledged stakes. The disclosure ensures transparency regarding the promoter’s leverage position, allowing market participants to assess the quality of the promoter’s holding more accurately.